EGFR and non-small cell lung carcinoma: In phase I-II trials, almonertinib demonstrated clinical benefits and minimal toxicity in patients with EGFR T790M-positive NSCLC, for whom the first generation of EGFR TKI treatment was ineffective [166,168].